NewEdge Wealth’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-5,466
Closed -$247K 598
2022
Q2
$247K Buy
5,466
+1,084
+25% +$56.2K 0.01% 497
2022
Q1
$333K Buy
4,382
+2,300
+110% +$201K 0.01% 353
2021
Q4
$310K Buy
+2,082
New +$319K 0.01% 338

Other funds holding TXG

NewEdge Wealth's TXG Position: Q3 2022 in Review

NewEdge Wealth sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 5,466 shares — an estimated $247K sold.

NewEdge Wealth first reported a position in TXG in Q4 2021 and held it in 3 quarters. The position peaked at $333K in Q1 2022. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • NewEdge Wealth reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • NewEdge Wealth sold 5,466 10x Genomics shares in Q3 2022, an estimated $247K.
  • NewEdge Wealth first reported a position in 10x Genomics in Q4 2021 and held it in 3 quarters.
  • NewEdge Wealth's 10x Genomics position peaked at $333K in Q1 2022.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on NewEdge Wealth's 13F filing for Q3 2022, filed 14 Nov 2022.